Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $85 per share, more than 40% below its peak level of over $145 seen in June of this year. In contrast, its closest peer, Eli Lilly stock (NYSE ...

CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant ...

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock.

Novo Nordisk (NVO) stock is tumbling 21% today after individuals who received the company's experimental weight-loss drug shed many fewer pounds than expected. Specifically, the weight of patients ...

The long-standing edge that Novo Nordisk has held in the obesity drug market was thrown into question Friday when the company reported results of a closely watched candidate that fell short of ...

Novo Nordisk’s next-generation obesity candidate led patients to lose a substantial amount of weight in a pivotal study but fell short of expectations, results that cast into doubt the future ...